From Population to Precision
Super Session 5
Tackling global health challenges requires that we move from ‘reactive’ to ‘proactive’ care, and that we personalize our approach. The practice of evidence-based medicine and the continued identification of new biomarkers are vital steps in improving disease diagnosis, improving the safety and efficacy of existing medicines, and in developing new medicines and targeted therapies. In this session, we discuss the needs and challenges from both industry and financial viewpoints.
Hosted by:
Oslo Cancer Cluster
Speaker(s):
Dr. Jutta Heix
-
Head of International Affairs, Oslo Cancer Cluster - Super Session Chair
Ms. Karin Conde-Knape
-
CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk
Ms. Carolina Haefliger
-
VP, Head Centre for Genomics Research, AstraZeneca
Dr. Patrick Sobocki
-
Investment Manager, Industrifonden
Mr. Karl Bergman
-
CEO, Elypta
Dr. Gupta Udatha
-
Project Coordinator, DIGI-B-CUBE
Dr. Falk Ehmann (TBC)
-
Chair Innovation Task Force, European Medicines Agency